BridgeBio Pharma recently reported a strong and accelerating launch of its heart drug Attruby, with rapid growth in unique patient prescriptions and prescribers, supported by compelling clinical ...
Hosted on MSN
Pfizer settles to delay Vyndamax generics until 2031
Pfizer has reached settlements with three generic drugmakers, pushing back U.S. market entry of Vyndamax copies until mid-2031, pending other litigation. The move preserves billions in annual revenue ...
Pfizer has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla, delaying generic competition for its blockbuster ATTR-CM drug Vyndamax until 2031. The move preserves ...
In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on BridgeBio Pharma, with a price target of $102.00. Claim 55% Off TipRanks. Unlock hedge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results